As disclosed in the final short form prospectus, filed on May 19, 2020, Tetra raised over CAD $9 million dollars to ensure it would have dedicated funds to start its phase 2 clinical trial in 2020 and ...

Alternavida to launch and fund 2 clinical sites in Mexico as part of the clinical research collaboration in the commercialization agreement Collaboration potentially allows Tetra to accelerate Phase 3 ...

OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Dr.

OTTAWA, ONTARIO--(Marketwired - May 23, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with ...

Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003. MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc.

Provides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products LONDON & MONTREAL--(BUSINESS WIRE)--Akanda Corp.

HCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma (HCC) OTTAWA, ON / ACCESSWIRE / June 2, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the ...

OTTAWA, ON, Sept. 8, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. (TBPMF) ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, ...

OTTAWA, ON, May 28, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to ...

Tetra Bio-Pharma Inc has raised $2 million in a private placement with Alumina Partners LLC. Formerly named GrowPros Cannabis Ventures Inc., Ottawa, Ontario-based Tetra Bio-Pharma is a consulting firm ...

Tetra Bio-Pharma Inc. TBP TBPMF, a leader in cannabinoid-derived drug discovery and development announced on Monday that it produced positive initial clinical data from its ongoing Phase 2 clinical ...